Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lapatinib combinations in recurrent HER2+ breast cancer brain metastases
NCT00437073Phase 2Terminated
- Sponsor
- GSK
- Start
- May 2007
- Primary completion
- Jan 2009
- Modality
- Small Molecules
- Countries
- 11
01
Overview
A Phase 2 trial of lapatinib in HER2-positive breast cancer, sponsored by GSK. Started May 2007; status: terminated.
02
Drugs
lapatinib
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT00437073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00437073.